SSTR2 and neuroendocrine neoplasm: In view of meningiomas’ overexpression of SSTR, especially SSTR2, [68Ga]Ga-labeled DOTA (i.e., somatostatin analogue) tracers targeting SSTR, primarily developed for neuroendocrine tumors, have been largely used to allow highly selected meningioma uptake, low healthy brain tissue uptake, and, thus, higher specificity in the tumor-to-background contrast with excellent tumor visualization [59,79].